Form 4: OptimizeRx Chief Product Officer Acquires Shares and Options

OptimizeRx's Chief Product Officer, Doug Besch, acquired 41,408 restricted stock units and 77,742 stock options on December 23, 2024.

Summary

• Doug Besch, Chief Product Officer of OptimizeRx Corp, reported acquiring 41,408 restricted stock units and 77,742 stock options on December 23, 2024.
• The restricted stock units were granted at a price of $0 and represent a contingent right to receive shares of OptimizeRx common stock.
• These restricted stock units will vest in three equal annual installments starting on December 23, 2025.
• The stock options have an exercise price of $4.83 and also vest in three equal annual installments beginning on December 23, 2025.
• The stock options expire on December 23, 2027.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns executive interests with company performance. The sentiment is neutral to positive.

Positives

• The acquisition of shares and options by a key executive like the Chief Product Officer can be seen as a positive sign of confidence in the company's future.

Future Outlook

The vesting schedule for the restricted stock units and stock options indicates a long-term incentive for the executive.

Industry Context

This type of equity grant is common practice for incentivizing key executives in publicly traded companies, particularly in the technology sector.

Comparison to Industry Standards

• Equity grants, including restricted stock units and stock options, are a standard component of executive compensation packages in the tech industry.
• Companies like Veeva Systems (VEEV) and Teladoc Health (TDOC), which operate in related healthcare technology spaces, also utilize similar equity-based compensation strategies to align executive interests with shareholder value.
• The vesting schedules, typically over a three to four year period, are also consistent with industry norms to encourage long-term commitment.

Stakeholder Impact

• The equity grants align the executive's interests with those of shareholders, potentially driving long-term value creation.
• Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

OptimizeRx, OPRX, stock options, restricted stock units, insider trading, executive compensation, equity securities, Doug Besch